{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:50:06Z","timestamp":1794329406074,"version":"4.9.0"},"reference-count":128,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","award":["57515880"],"award-info":[{"award-number":["57515880"]}],"id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK1739"],"award-info":[{"award-number":["GRK1739"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG-IL51.10"],"award-info":[{"award-number":["DFG-IL51.10"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["IL51.11"],"award-info":[{"award-number":["IL51.11"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008349","name":"Universit\u00e4t Duisburg-Essen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["02NUK043B"],"award-info":[{"award-number":["02NUK043B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["02NUK054B"],"award-info":[{"award-number":["02NUK054B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["02NUK037B"],"award-info":[{"award-number":["02NUK037B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.omton.2025.200934","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T12:23:37Z","timestamp":1736857417000},"page":"200934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Reversing regulatory safeguards: Targeting the ATR pathway to overcome PARP inhibitor resistance"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3161-0253","authenticated-orcid":false,"given":"Xixi","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashish","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stuschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1152-5342","authenticated-orcid":false,"given":"George","family":"Iliakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2025.200934_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.seminoncol.2023.09.005","article-title":"PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics","volume":"51","author":"Zeng","year":"2024","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.omton.2025.200934_bib2","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.omton.2025.200934_bib3","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1158\/1535-7163.MCT-17-0836","article-title":"Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks","volume":"17","author":"Soni","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.omton.2025.200934_bib4","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.3390\/cancers14225619","article-title":"BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy","volume":"14","author":"Soni","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2025.200934_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110475","article-title":"Talazoparib enhances resection at DSBs and renders HR-proficient cancer cells susceptible to Pol\u03b8 inhibition","volume":"200","author":"Lin","year":"2024","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.omton.2025.200934_bib6","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.200934_bib7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.omton.2025.200934_bib8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings","volume":"5","author":"Helleday","year":"2011","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.omton.2025.200934_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","article-title":"Transcription-replication conflicts underlie sensitivity to PARP inhibitors","volume":"628","author":"Petropoulos","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.200934_bib10","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.200934_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.semcancer.2016.03.003","article-title":"DNA double-strand-break repair in higher eukaryotes and its role in genomic instability and cancer: Cell cycle and proliferation-dependent regulation","volume":"37\u201338","author":"Mladenov","year":"2016","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.omton.2025.200934_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2025.200934_bib13","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.200934_bib14","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1158\/0008-5472.CAN-11-3417","article-title":"Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1","volume":"72","author":"Ying","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.200934_bib15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.molcel.2018.06.004","article-title":"The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication","volume":"71","author":"Hanzlikova","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omton.2025.200934_bib16","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2025.200934_bib17","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1101\/gad.348479.121","article-title":"The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1\/2-deficient cells","volume":"35","author":"Simoneau","year":"2021","journal-title":"Genes Dev."},{"key":"10.1016\/j.omton.2025.200934_bib18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.omton.2025.200934_bib19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.gde.2021.07.003","article-title":"An extending ATR-CHK1 circuitry: the replication stress response and beyond","volume":"71","author":"Simoneau","year":"2021","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.omton.2025.200934_bib20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.celrep.2019.09.008","article-title":"ATR Signaling Uncouples the Role of RAD51 Paralogs in Homologous Recombination and Replication Stress Response","volume":"29","author":"Saxena","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2025.200934_bib21","doi-asserted-by":"crossref","first-page":"8859","DOI":"10.1093\/nar\/gkx571","article-title":"A phosphorylation-and-ubiquitylation circuitry driving ATR activation and homologous recombination","volume":"45","author":"Dubois","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2025.200934_bib22","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1158\/0008-5472.CAN-20-2723","article-title":"ATR\/ATM-Mediated Phosphorylation of BRCA1 T1394 Promotes Homologous Recombinational Repair and G(2)-M Checkpoint Maintenance","volume":"81","author":"Foo","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.200934_bib23","article-title":"Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy","volume":"12","author":"Xu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2025.200934_bib24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41416-024-02745-0","article-title":"ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors","volume":"131","author":"Smith","year":"2024","journal-title":"Br. J. Cancer."},{"key":"10.1016\/j.omton.2025.200934_bib25","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1083\/jcb.201809012","article-title":"Advances in understanding DNA processing and protection at stalled replication forks","volume":"218","author":"Rickman","year":"2019","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.omton.2025.200934_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112792","article-title":"ATR protects ongoing and newly assembled DNA replication forks through distinct mechanisms","volume":"42","author":"Leung","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2025.200934_bib27","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature18325","article-title":"Replication fork stability confers chemoresistance in BRCA-deficient cells","volume":"535","author":"Ray Chaudhuri","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.200934_bib28","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41594-020-0418-4","article-title":"Reconstitution of translesion synthesis reveals a mechanism of eukaryotic DNA replication restart","volume":"27","author":"Guilliam","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.omton.2025.200934_bib29","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1093\/nar\/gkab176","article-title":"Repriming DNA synthesis: an intrinsic restart pathway that maintains efficient genome replication","volume":"49","author":"Bainbridge","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2025.200934_bib30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nrm3935","article-title":"Replication fork reversal in eukaryotes: from dead end to dynamic response","volume":"16","author":"Neelsen","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omton.2025.200934_bib31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.molcel.2017.09.036","article-title":"Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers","volume":"68","author":"Taglialatela","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omton.2025.200934_bib32","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1101\/gad.214080.113","article-title":"ATR phosphorylates SMARCAL1 to prevent replication fork collapse","volume":"27","author":"Couch","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.omton.2025.200934_bib33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1101\/gad.178459.111","article-title":"SMARCAL1 catalyzes fork regression and Holliday junction migration to maintain genome stability during DNA replication","volume":"26","author":"B\u00e9tous","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.omton.2025.200934_bib34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cell.2011.03.041","article-title":"Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11","volume":"145","author":"Schlacher","year":"2011","journal-title":"Cellule"},{"key":"10.1016\/j.omton.2025.200934_bib35","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nsmb.3252","article-title":"FANCD2 limits replication stress and genome instability in cells lacking BRCA2","volume":"23","author":"Michl","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.omton.2025.200934_bib36","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ncb3035","article-title":"RASSF1A-LATS1 signalling stabilizes replication forks by restricting CDK2-mediated phosphorylation of BRCA2","volume":"16","author":"Pefani","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.omton.2025.200934_bib37","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.molcel.2013.07.023","article-title":"FANCD2 binds MCM proteins and controls replisome function upon activation of s phase checkpoint signaling","volume":"51","author":"Lossaint","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omton.2025.200934_bib38","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/nar\/gkm1052","article-title":"ATR-dependent pathways control hEXO1 stability in response to stalled forks","volume":"36","author":"El-Shemerly","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2025.200934_bib39","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.molcel.2019.04.003","article-title":"Ca(2+)-Stimulated AMPK-Dependent Phosphorylation of Exo1 Protects Stressed Replication Forks from Aberrant Resection","volume":"74","author":"Li","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omton.2025.200934_bib40","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1016\/j.molcel.2021.05.027","article-title":"EXO5-DNA structure and BLM interactions direct DNA resection critical for ATR-dependent replication restart","volume":"81","author":"Hambarde","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omton.2025.200934_bib41","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.molcel.2019.10.010","article-title":"ATR Protects the Genome against R Loops through a MUS81-Triggered Feedback Loop","volume":"77","author":"Matos","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omton.2025.200934_bib42","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","article-title":"Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids","volume":"8","author":"Hill","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2025.200934_bib43","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.molcel.2020.12.049","article-title":"TopBP1 assembles nuclear condensates to switch on ATR signaling","volume":"81","author":"Frattini","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omton.2025.200934_bib44","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1091\/mbc.e04-11-1006","article-title":"ATRIP binding to replication protein A-single-stranded DNA promotes ATR-ATRIP localization but is dispensable for Chk1 phosphorylation","volume":"16","author":"Ball","year":"2005","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.omton.2025.200934_bib45","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.molcel.2016.12.007","article-title":"Coupling of Homologous Recombination and the Checkpoint by ATR","volume":"65","author":"Buisson","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omton.2025.200934_bib46","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12943-021-01382-y","article-title":"Long non-coding RNA ANRIL promotes homologous recombination-mediated DNA repair by maintaining ATR protein stability to enhance cancer resistance","volume":"20","author":"Liu","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omton.2025.200934_bib47","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1101\/gad.290957.116","article-title":"ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells","volume":"31","author":"Yazinski","year":"2017","journal-title":"Genes Dev."},{"key":"10.1016\/j.omton.2025.200934_bib48","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1038\/s41467-019-10993-5","article-title":"Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma","volume":"10","author":"Ning","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2025.200934_bib49","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","article-title":"53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks","volume":"141","author":"Bunting","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.omton.2025.200934_bib50","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41556-018-0140-1","article-title":"Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells","volume":"20","author":"Dev","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.omton.2025.200934_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcaa006","article-title":"Intrinsic ATR signaling shapes DNA end resection and suppresses toxic DNA-PKcs signaling","volume":"2","author":"Dibitetto","year":"2020","journal-title":"NAR Cancer"},{"key":"10.1016\/j.omton.2025.200934_bib52","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.molcel.2012.11.020","article-title":"Activation of DSB processing requires phosphorylation of CtIP by ATR","volume":"49","author":"Peterson","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omton.2025.200934_bib53","doi-asserted-by":"crossref","first-page":"10779","DOI":"10.1074\/jbc.M116.772475","article-title":"DNA-damage-induced degradation of EXO1 exonuclease limits DNA end resection to ensure accurate DNA repair","volume":"292","author":"Tomimatsu","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omton.2025.200934_bib54","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13046-023-02829-4","article-title":"ATR-binding lncRNA ScaRNA2 promotes cancer resistance through facilitating efficient DNA end resection during homologous recombination repair","volume":"42","author":"Chen","year":"2023","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.200934_bib55","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.4161\/cc.6389","article-title":"The multiple facets of the intra-S checkpoint","volume":"7","author":"Grallert","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.omton.2025.200934_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/genes10020094","article-title":"On the Interplay of the DNA Replication Program and the Intra-S Phase Checkpoint Pathway","volume":"10","author":"Ciardo","year":"2019","journal-title":"Genes"},{"key":"10.1016\/j.omton.2025.200934_bib57","article-title":"The intra-S phase checkpoint directly regulates replication elongation to preserve the integrity of stalled replisomes","volume":"118","author":"Liu","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2025.200934_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103662","article-title":"Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic","volume":"28","author":"Priya","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.omton.2025.200934_bib59","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev-genet-121415-121658","article-title":"Functions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway","volume":"50","author":"Yazinski","year":"2016","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.omton.2025.200934_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23147506","article-title":"ATR Contributes More Than ATM in Intra-S-Phase Checkpoint Activation after IR, and DNA-PKcs Facilitates Recovery: Evidence for Modular Integration of ATM\/ATR\/DNA-PKcs Functions","volume":"23","author":"Soni","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2025.200934_bib61","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2641","article-title":"p53 mutations in cancer","volume":"15","author":"Muller","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.omton.2025.200934_bib62","doi-asserted-by":"crossref","first-page":"8255","DOI":"10.1038\/s41598-019-44771-6","article-title":"Radiation-dose-dependent functional synergisms between ATM, ATR and DNA-PKcs in checkpoint control and resection in G(2)-phase","volume":"9","author":"Mladenov","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2025.200934_bib63","article-title":"DNA-PKcs and ATM epistatically suppress DNA end resection and hyperactivation of ATR-dependent G(2)-checkpoint in S-phase irradiated cells","volume":"9","author":"Mladenov","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2025.200934_bib64","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7150\/thno.88899","article-title":"NRF2 promotes radiation resistance by cooperating with TOPBP1 to activate the ATR-CHK1 signaling pathway","volume":"14","author":"Sun","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.omton.2025.200934_bib65","doi-asserted-by":"crossref","first-page":"9109","DOI":"10.1093\/nar\/gkaa631","article-title":"NRF2 preserves genomic integrity by facilitating ATR activation and G2 cell cycle arrest","volume":"48","author":"Sun","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2025.200934_bib66","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.aap9346","article-title":"An intrinsic S\/G2 checkpoint enforced by ATR","volume":"361","author":"Saldivar","year":"2018","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.omton.2025.200934_bib67","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/1878-0261.12573","article-title":"Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells","volume":"13","author":"Schoonen","year":"2019","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.omton.2025.200934_bib68","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2025.200934_bib69","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2025.200934_bib70","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.bbrc.2016.06.133","article-title":"MiR-27b is epigenetically downregulated in tamoxifen resistant breast cancer cells due to promoter methylation and regulates tamoxifen sensitivity by targeting HMGB3","volume":"477","author":"Li","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omton.2025.200934_bib71","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41419-022-04670-7","article-title":"HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer","volume":"13","author":"Ma","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omton.2025.200934_bib72","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146256","article-title":"Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models","volume":"131","author":"Mehibel","year":"2021","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omton.2025.200934_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249715","article-title":"PARP Inhibition Increases the Reliance on ATR\/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness","volume":"21","author":"Gralewska","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2025.200934_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-50151-y","article-title":"Targeted inhibition of the ATR\/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2(MUT) ovarian cancer cells","volume":"13","author":"Biega\u0142a","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2025.200934_bib75","article-title":"The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous BRCA(MUT) and BRCA(WT) Ovarian Cancer Cells","volume":"11","author":"Gralewska","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.omton.2025.200934_bib76","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","article-title":"Targeting the ATR\/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models","volume":"23","author":"Kim","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.200934_bib77","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","article-title":"Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer","volume":"163","author":"Shah","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.omton.2025.200934_bib78","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","article-title":"Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer","volume":"29","author":"Wethington","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.200934_bib79","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1200\/PO.20.00439","article-title":"Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)","volume":"5","author":"Mahdi","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.omton.2025.200934_bib92","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/cncr.35059","article-title":"Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer","volume":"130","author":"Park","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2025.200934_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100814","article-title":"34O ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss: Results from the ENGOT\/GYN1\/NCRI ATARI trial","volume":"8","author":"Banerjee","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.omton.2025.200934_bib105","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2022.40.6_suppl.088","article-title":"Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial)","volume":"40","author":"Reichert","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2025.200934_bib80","doi-asserted-by":"crossref","first-page":"S542","DOI":"10.1016\/j.annonc.2023.09.1996","article-title":"821TiP Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced\/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis)","volume":"34","author":"Shapiro","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omton.2025.200934_bib81","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/1538-7445.AM2021-1374","article-title":"The novel PARP1-selective inhibitor AZD5305 has reduced hematological toxicity when compared to PARP1\/2 inhibitors in pre-clinical models","volume":"81","author":"Gill","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.200934_bib82","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-CT007","article-title":"Abstract CT007: PETRA: first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1\/2, PALB2 or RAD51C\/D mutations","volume":"82","author":"Yap","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.200934_bib83","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1158\/1538-7445.AM2024-946","article-title":"Landscape of HRD aberration in EGFR mutated lung cancer and the role of PARP-inhibitor in EGFR mutated lung cancer with HRD aberration","volume":"84","author":"Kim","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.200934_bib84","doi-asserted-by":"crossref","first-page":"62","DOI":"10.21037\/cco-23-58","article-title":"Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis","volume":"12","author":"Olivares-Hern\u00e1ndez","year":"2023","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.200934_bib85","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1002\/cam4.5148","article-title":"Mutational landscape of homologous recombination-related genes in small-cell lung cancer","volume":"12","author":"Wu","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.omton.2025.200934_bib86","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1158\/2159-8290.CD-12-0112","article-title":"Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1","volume":"2","author":"Byers","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2025.200934_bib87","article-title":"PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications","volume":"153","author":"Wang","year":"2022","journal-title":"Biomedicine\u00a0& pharmacotherapy\u00a0= Biomedecine\u00a0& pharmacotherapie"},{"key":"10.1016\/j.omton.2025.200934_bib88","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1158\/1535-7163.MCT-23-0402","article-title":"The novel ATR inhibitor M1774 induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs","volume":"23","author":"Jo","year":"2024","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.omton.2025.200934_bib89","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41416-019-0565-8","article-title":"Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated\/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells","volume":"121","author":"Jette","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2025.200934_bib90","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","article-title":"Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells","volume":"39","author":"Lloyd","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.omton.2025.200934_bib91","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41416-020-0931-6","article-title":"Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models","volume":"123","author":"Tran Chau","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2025.200934_bib93","first-page":"161","article-title":"Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers","volume":"13","author":"Li","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.omton.2025.200934_bib94","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1535-7163.MCT-21-0615","article-title":"RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors","volume":"21","author":"Roulston","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.omton.2025.200934_bib95","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.200934_bib96","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1158\/1078-0432.CCR-22-0568","article-title":"Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance","volume":"28","author":"Serra","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.200934_bib97","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2020.10.029","article-title":"Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors","volume":"79","author":"Neeb","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.omton.2025.200934_bib98","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1136\/gutjnl-2019-319970","article-title":"Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer","volume":"70","author":"Gout","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.omton.2025.200934_bib99","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1535-7163.MCT-20-0365","article-title":"Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination\u2013Proficient Pancreatic Cancer","volume":"20","author":"Parsels","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.omton.2025.200934_bib100","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2021.05.029","article-title":"ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer","volume":"516","author":"Nam","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omton.2025.200934_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246215","article-title":"Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells","volume":"13","author":"King","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2025.200934_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051095","article-title":"ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms","volume":"12","author":"Southgate","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2025.200934_bib103","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcab018","article-title":"Targeting IDH1\/2 mutant cancers with combinations of ATR and PARP inhibitors","volume":"3","author":"Sule","year":"2021","journal-title":"NAR Cancer"},{"key":"10.1016\/j.omton.2025.200934_bib106","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1140321","article-title":"ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage","volume":"316","author":"Matsuoka","year":"2007","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.omton.2025.200934_bib107","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrm3546","article-title":"The ATM protein kinase: regulating the cellular response to genotoxic stress, and more","volume":"14","author":"Shiloh","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omton.2025.200934_bib108","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.dnarep.2014.01.010","article-title":"Functional overlaps between XLF and the ATM-dependent DNA double strand break response","volume":"16","author":"Kumar","year":"2014","journal-title":"DNA Repair"},{"key":"10.1016\/j.omton.2025.200934_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003667","article-title":"ATM release at resected double-strand breaks provides heterochromatin reconstitution to facilitate homologous recombination","volume":"9","author":"Geuting","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.omton.2025.200934_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003277","article-title":"The interaction of CtIP and Nbs1 connects CDK and ATM to regulate HR-mediated double-strand break repair","volume":"9","author":"Wang","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.omton.2025.200934_bib111","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/1878-0261.13020","article-title":"DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies","volume":"16","author":"Rominiyi","year":"2022","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.omton.2025.200934_bib112","doi-asserted-by":"crossref","DOI":"10.3390\/cells11010063","article-title":"Shift in G(1)-Checkpoint from ATM-Alone to a Cooperative ATM Plus ATR Regulation with Increasing Dose of Radiation","volume":"11","author":"Li","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.omton.2025.200934_bib113","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1158\/0008-5472.CAN-16-3398","article-title":"ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma","volume":"77","author":"Schmitt","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.200934_bib114","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-19-3126","article-title":"ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer","volume":"80","author":"Rafiei","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.200934_bib115","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/1535-7163.MCT-22-0685","article-title":"Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors","volume":"22","author":"Turchick","year":"2023","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.omton.2025.200934_bib116","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg2263","article-title":"ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer","volume":"9","author":"Zhou","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omton.2025.200934_bib117","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1038\/s41467-024-48715-1","article-title":"H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours","volume":"15","author":"Dibitetto","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2025.200934_bib118","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.1038\/s41467-022-33123-0","article-title":"Mechanistic understanding of human SLFN11","volume":"13","author":"Metzner","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2025.200934_bib119","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.molcel.2018.01.012","article-title":"SLFN11 Blocks Stressed Replication Forks Independently of ATR","volume":"69","author":"Murai","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omton.2025.200934_bib120","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2019.05.009","article-title":"Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies","volume":"201","author":"Murai","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.omton.2025.200934_bib121","doi-asserted-by":"crossref","first-page":"76534","DOI":"10.18632\/oncotarget.12266","article-title":"Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition","volume":"7","author":"Murai","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2025.200934_bib122","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2015654118","article-title":"SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR\/CHK1 inhibitors","volume":"118","author":"Jo","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2025.200934_bib123","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41594-018-0142-5","article-title":"DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs","volume":"25","author":"Li","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.omton.2025.200934_bib124","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1042\/BST20140079","article-title":"Ribonuclease H2 in health and disease","volume":"42","author":"Reijns","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.omton.2025.200934_bib125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41586-018-0291-z","article-title":"CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions","volume":"559","author":"Zimmermann","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.200934_bib126","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1038\/s41388-018-0606-4","article-title":"Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition","volume":"38","author":"Wang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.omton.2025.200934_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111081","article-title":"Guiding ATR and PARP inhibitor combinationswith chemogenomic screens","volume":"40","author":"Zimmermann","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2025.200934_bib128","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl9794","article-title":"RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer","volume":"8","author":"Miao","year":"2022","journal-title":"Sci. Adv."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925000037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925000037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:38:03Z","timestamp":1778938683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329925000037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2950329925000037"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2025.200934","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversing regulatory safeguards: Targeting the ATR pathway to overcome PARP inhibitor resistance","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2025.200934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"200934"}}